Gerin Prince on Muck Rack

Gerin Prince

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Gerin

Contact Gerin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling - Nature Communications

|
By Dominik Schmidt, Gerin Prince, Geoffroy Andrieux, Nikolas von Bubnoff, Teresa Poggio
| Nature
Abstract Ruxolitinib is a potent JAK1/JAK2 inhibitor, approved for the treatment of primary myelofibrosis (PMF) patients based on the concept of inhibition of oncogenic signaling. However, the effect of ruxolitinib on JAK2-V617F allelic burden is modest, suggesting that inhibition of JAK2-V617F signaling-driven clone expansion is not the main mechanism of action.
Open in Who Shared Issue with article?

Ruxolitinib mediated paradoxical JAK2 hyperphosphorylation is due to the protection of activation loop tyrosines from phosphatases - Leukemia

|
By Sivahari P. Gorantla, Gerin Prince, Wencke Walter, Torsten Haferlach, Niklas Gebauer, Hauke Busch, Lorenz Oelschläger
| Nature
Abstract Myelofibrosis (MF) in 50% of cases is driven by an activating JAK2 mutation, mostly V617F. Ruxolinitib is approved for the treatment of MF. Responses to ruxolitinib in MF are of limited duration. Unexpectedly, treatment of JAK2-V617F expressing cells with ruxolitinib causes paradoxical hyperphosphorylation of JAK2 at activation loop Tyr1007/Tyr1008. The significance of ruxolitinib-induced JAK2 hyperphosphorylation is not well understood.
Open in Who Shared Issue with article?

Type II JAK2 Inhibitor CHZ‐868 and HSP90 Inhibitors Are Potent towards the Ruxolitinib Resistant JAK2 Variants in JAK2 Driven Myeloproliferative Neoplasms

|
By Sivahari Prasad Gorantla, Gerin Prince, Jasmin Osius, Dhurvas Dinesh
| preprints.org
Preprint Article Version 1 This version is not peer-reviewed Version 1 : Received: 29 December 2023 / Approved: 3 January 2024 / Online: 3 January 2024 (14:39:52 CET) Gorantla, S.P.; Prince, G.; Osius, J.; Dinesh, D.; Boddu, V.K.; Duyster, J.; Von Bubnoff, N. Type II JAK2 Inhibitor CHZ‐868 and HSP90 Inhibitors Are Potent towards the Ruxolitinib Resistant JAK2 Variants in JAK2 Driven Myeloproliferative Neoplasms. Preprints 2024, 2024010265.
Open in Who Shared Issue with article?
See all 3 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Gerin

Contact Gerin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified